Clinical Trials Logo

Resectable Carcinoma clinical trials

View clinical trials related to Resectable Carcinoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05802407 Recruiting - Pancreatic Cancer Clinical Trials

The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer

MAP-02
Start date: February 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in resected pancreatic cancer. The main questions it aims to answer are: - prognostic value of baseline MRD; - the role of MRD dynamic changes after treatment in guiding treatment. Peripheral blood derived from participants will be obtained for MRD test before adjuvant chemotherapy initiation and at the first imaging assessment after chemotherapy.